Toggle light / dark theme

An omega-3 paradox: When ‘healthy fats’ shut down defenses against cancer

Omega fatty acids have long been recognized for their benefits: supporting cardiovascular health, reducing systemic inflammation, and promoting brain development and cognitive function. But scientists now warn of a long-unrecognized downside to these compounds when it comes to cancer and immunotherapy.

New preclinical experiments by medical investigators in the Vascular Biology and Therapeutic Program at Yale University School of Medicine show that omega fatty acids can blunt the cancer-killing capabilities of the immune system’s natural killer cells.

Their research is part of a growing body of evidence suggesting that well-known—and largely beneficial—fatty acids can circumvent the body’s defenses and promote cancer growth.

Why some young ants start hunting and caring for others early

Some insects, including honeybees and ants, live in highly organized colonies where individuals take on specific roles. In many ant societies, young adult workers typically care for developing young inside the nest before beginning to forage, or search for food, outside it. Some ant species, however, start hunting for food as soon as they reach adulthood, without undergoing a transition period.

One example is Stigmatomma pallipes, a species belonging to a group commonly called Dracula ants because adults can pierce the skin of their developing young and drink a bloodlike fluid called hemolymph. The age-independent behavior of these ants was first reported in a Science paper published in 1978 by Dr. James Traniello, who is now a professor of biology at Boston University.

Researchers at Boston University recently tried to better understand how the brain development of S. pallipes workers contributes to this early readiness for work. Their findings, published in Proceedings of the Royal Society B, suggest that regions in the brains of S. pallipes reach their largest size during the pupal stage, when immature ants transition into adulthood.

There’s No Lab Test for Depression—But a Landmark Study Aims To Change This

A landmark, multi-year observational study will profile thousands of individuals with depression, bringing together genomics, neuroimaging, clinical assessments, and patient-reported outcomes to identify biomarkers that can guide drug development and personalize depression care.

Why has psychiatry lacked major therapeutic advances?

The first antidepressants were discovered by accident, when clinicians noticed that a tuberculosis drug, iproniazid, lifted the mood of patients.

Millions of adults have this common condition. It’s linked to cognitive decline

A group of international scientists have found that people with attention-deficit/hyperactivity disorder (ADHD) could be at higher risk of developing cognitive impairment—one of the signs of dementia.

They also found that those with ADHD who developed cognitive impairment experienced worse health outcomes as a result of the disease as well.

The findings build on previous studies discovering an association between adult ADHD and a higher risk of developing dementia, and experts say this highlights the need for more research to understand the connection, as well as greater and more targeted monitoring and care for those with ADHD as they get older.

Two Alzheimer’s Drugs Are Now Being Tested to Prevent Dementia Before It Starts

Two drugs sit at the center of the current prevention push. Lecanemab, sold under the brand name Leqembi, received full FDA approval in July 2023 as the first therapy proven to slow cognitive decline by clearing amyloid from the brain. The drug is made by the pharmaceutical companies Eisai and Biogen, and its Phase 3 data came from the Clarity AD trial, published in The New England Journal of Medicine. In patients with early Alzheimer’s, lecanemab reduced brain amyloid levels and slowed cognitive decline by 27% over an 18-month period. The AHEAD 3–45 trial is now taking that same drug into a preclinical population – people with no symptoms at all.

The second drug, donanemab (brand name Kisunla), came next. Manufactured by Eli Lilly, it targets amyloid beta administered intravenously and received FDA approval in July 2024. Its Phase 3 clinical trial data, published in JAMA, was striking. Cognitive and functional decline slowed on all outcome measures: 35% on the iADRS scale, 37% on the CDR-SB, 32% on the ADAS-Cog13, and 40% on ADCS-iADL measures – all statistically significant results. Looking at the data another way, 47% of people on donanemab stayed stable on the CDR-SB over one year, compared with 29% on placebo.

Both approvals share an important boundary. Both lecanemab and donanemab are currently approved for early symptomatic Alzheimer’s disease – specifically, patients with mild cognitive impairment or mild dementia with confirmed amyloid pathology. The prevention trials now underway aim to move that window back considerably, to people who haven’t yet developed any symptoms at all.

Scientists discover a human brain gene that can jump through DNA

“Genes that come from transposable elements and that are repurposed for cellular functions are typically no longer transposable,” said Cedric Feschotte, a senior author of the study. “BC200 was itself created from a mobile element but has retained its mobility and yet it is also clearly serving a cellular function. Somehow evolution hasn’t been able to untangle these two things.”

A Rare Genetic Jump Into a Virus

Scientists have documented a handful of cases in other species in which transposable elements moved into viruses. One early example came in the late 1980s, when researchers working with cultured moth cells observed a transposon moving from those cells into a baculovirus, a type of virus that infects insects.

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. Data from the first three treated patients demonstrate successful penetration of the human blood-brain barrier (BBB) with intra-tumoral drug concentrations in line with preclinical models, alongside good tolerability where the first patient has received five monthly doses to date without any major drug-related toxicity.

The blood-brain barrier represents one of the greatest hurdles in neuro-oncology, causing more than 90 percent of conventional systemic cancer drugs to fail because they cannot reach the brain. By confirming meaningful, BBB penetration and delivery of a cytotoxic payload into brain tumor cells in the first patients, the findings provide a strong indication of a clinical proof-of-concept for the PDC platform’s mechanism in solid brain tumors.

“Reaching our primary objective to confirm that our PDC technology successfully crosses the human blood-brain barrier is a major breakthrough for Oncopeptides,” says Sofia Heigis, CEO of Oncopeptides. “For decades, the blood-brain barrier has locked out effective treatments for glioblastoma patients. Demonstrating meaningful drug penetration in resected brain tumors in patients after a single dose validates the fundamental strength and versatility of our platform, transforming our brain cancer program from an ambitious basic scientific premise into a true, clinically justified, opportunity.”

Bonn researchers successfully rejuvenate human cells in a test tube

Researchers from the University Hospital of Bonn and the University of Bonn have succeeded in dramatically rejuvenating human cells in a test tube. To do so, they directly reprogrammed red blood cell precursors into stem cells from which neurons can be derived. During this process, the molecular clocks that indicate a cell’s age were reset. For example, blood cells from an 80-year-old were transformed into stem cells with a molecular age of less than 20 years. Since this rejuvenation process occurred very slowly, it is well-suited for a more detailed investigation of the underlying mechanisms. The results have been published in the journal Aging Cell.

The human body contains hundreds of different cell types. They all originate from the fertilized egg and therefore share the same genetic makeup. However, in the course of their development, they were committed to a specific fate: a skin cell cannot naturally become a liver cell, nor can a blood cell become a nerve cell.

Today, however, it is possible to reverse this determination in the laboratory. For example, nerve tissue can be grown from a skin cell, which may one day be used to treat neurodegenerative diseases. To achieve this reprogramming, researchers use a cocktail of various transcription factors. These factors cause the cell to read different genetic instructions and thus embark on a different developmental path.

The Steel Was Never Real

7 review: how falling walls between science, bodies, and AI are changing everything.

https://youtu.be/tNXNZLZI7Us](https://youtu.be/tNXNZLZI7Us)

*Oct 10, 2026 • S7 E75 • 50:52*

What if the walls between the sciences were never real? 🗄️🔥

After 75 deep dives, Heliox found a hidden pattern: the best answers live in the overlap between disciplines.

In “The Steel Was Never Real,” you’ll hear:

• How a Bayesian model revealed that two identical heart attacks can have completely different biological causes.